Top Earnings Beats For the Week Ending November 10 2017

Below are the top earnings and/or revenue beats for the week ending November 10, 2017. The table below is sorted by the biggest beats in descending order (at the top).
Continue reading “Top Earnings Beats For the Week Ending November 10 2017”

AMN Healthcare Services Pocket Pivot and Rising Large Players Volume

Strong technical setup with bullish sentiment from analysts. The company is also a strong seasonal play. The company was also recently ranked #11 on Fortune’s 100 Fastest Growing Companies list.

AMN Healthcare Services chart shows a beautiful setup with rising large players volume and a pocket pivot signal.

AMN Healthcare Services is also a good seasonal play. Over the next 10 weeks, AMN Healthcare Services has on average historically risen by 9.4% based on the past 15 years of stock performance. AMN Healthcare Services has risen higher in 12 of those 15 years over the next 10 week period, corresponding to a historical probability of 80%.

USANA Health Sciences Price Target Raised by Pivotal Research

Pivotal Research raised USANA Health Sciences price target to $80 from $70 which represents 16.4% upside from the current price of $68.70. Pivotal Research has a Buy rating on the stock.

The upgrade from Pivotal Research came after USANA Health Sciences reported its quarterly earnings results on Tuesday, October 24, 2017. The company reported EPS of $1.02 versus the consensus estimate of $0.91. Revenue also beat coming in at $261.77 million for the quarter, versus the consensus estimate of $259.52 million.

Exelixis Gets FDA Priority Review for Cabomteyx

The FDA has granted priority review for Exelixis Cabomteyx. The sNDA seeks approval of Cabometyx for patients with previously untreated advanced renal cell carcinoma (RCC). The FDA determined the sNDA to be sufficiently complete. This means an FDA approval decision will be made by Feb. 15, 2018.

Cryoport Stock Gets Janney Montgomery Scott Price Target of $12

Cryoport stock received a price target hike from Janney Montgomery Scott to $12 which is 42% upside from the previous close of $8.45.

Cryoport provides cryogenic logistics solutions to the life sciences industry through its packaging, information technology, and cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.

If someone wants to ship something cryogenically using UPS, FedEx, or DHL, they are directed to Cryoport by these shipping companies.

A whopping 70% of Cryoport's business comes from biopharma companies. About 15% comes from human reproduction needs and another 15% comes from animal health needs.

Centene Gets S&P Rating Upgrade to BB+ from BB

Sofi AI Market Sentiment Gauge

Sofi AI Market Sentiment Gauge

Market is neither overbought or oversold.